Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study
No Thumbnail Available
Identifiers
Date
2019-04-01
Authors
Owonikoko, T. K.
Kim, H. R.
Govindan, R.
Ready, N.
Reck, M.
Peters, S.
Dakhil, S. R.
Navarro, A.
Rodriguez-Cid, J.
Schenker, M.
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Oxford univ press
Metrics
Export
